20 research outputs found
Interpreting change from patient reported outcome (PRO) endpoints: patient global ratings of concept versus patient global ratings of change, a case study among osteoporosis patients
Patient-reported outcomes from a randomized, active-controlled, open-label, phase 3 trial of burosumab versus conventional therapy in children with X-linked hypophosphatemia
Changing to burosumab, a monoclonal antibody targeting fibroblast growth factor 23, significantly improved phosphorus homeostasis, rickets, lower-extremity deformities, mobility, and growth versus continuing oral phosphate and active vitamin D (conventional therapy) in a randomized, open-label, phase 3 trial involving children aged 1-12 years with X-linked hypophosphatemia. Patients were randomized (1:1) to subcutaneous burosumab or to continue conventional therapy. We present patient-reported outcomes (PROs) from this trial for children aged ≥ 5 years at screening (n = 35), using a Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaire and SF-10 Health Survey for Children. PROMIS pain interference, physical function mobility, and fatigue scores improved from baseline with burosumab at weeks 40 and 64, but changed little with continued conventional therapy. Pain interference scores differed significantly between groups at week 40 (- 5.02, 95% CI - 9.29 to - 0.75; p = 0.0212) but not at week 64. Between-group differences were not significant at either week for physical function mobility or fatigue. Reductions in PROMIS pain interference and fatigue scores from baseline were clinically meaningful with burosumab at weeks 40 and 64 but not with conventional therapy. SF-10 physical health scores (PHS-10) improved significantly with burosumab at week 40 (least-squares mean [standard error] + 5.98 [1.79]; p = 0.0008) and week 64 (+ 5.93 [1.88]; p = 0.0016) but not with conventional therapy (between-treatment differences were nonsignificant). In conclusion, changing to burosumab improved PRO measures, with statistically significant differences in PROMIS pain interference at week 40 versus continuing with conventional therapy and in PHS-10 at weeks 40 and 64 versus baseline
A Comparison of Dietary Intake Between Individuals Undergoing Maintenance Hemodialysis in the United Kingdom and China
OBJECTIVE: Protein-energy wasting is highly prevalent in people with end-stage kidney disease receiving regular hemodialysis. Currently, it is unclear what the optimal nutritional recommendations are, which is further complicated by differences in dietary patterns between countries. The aim of the study was to understand and compare dietary intake between individuals receiving hemodialysis in Leicester, UK and Nantong, China.
METHODS: The study assessed 40 UK and 44 Chinese participants' dietary intake over a period of 14 days using 24-hour diet recall interviews. Nutritional blood parameters were obtained from medical records. Food consumed by participants in the UK and China was analyzed using the Nutritics and Nutrition calculator to quantify nutritional intake.
RESULTS: Energy and protein intake were comparable between UK and Chinese participants, but with both below the recommended daily intake. Potassium intake was higher in UK participants compared to Chinese participants (2,115 [888] versus 1,159 [861] mg/d; P < .001), as was calcium (618 [257] versus 360 [312] mg/d; P < .001) and phosphate intake (927 [485] versus 697 [434] mg/d; P = .007). Vitamin C intake was lower in UK participants compared to their Chinese counterparts (39 [51] versus 64 [42] mg/d; P = .024). Data are reported here as median (interquartile range).
CONCLUSION: Both UK and Chinese hemodialysis participants have insufficient protein and energy in their diet. New strategies are required to increase protein and energy intakes. All participants had inadequate daily intake of vitamins C and D; there may well be a role in the oral supplementation of these vitamins, and further studies are urgently needed
Patient Reported Outcome (PRO) assessment in epilepsy:A review of epilepsy-specific PROs according to the Food and Drug Administration (FDA) regulatory requirements
Despite collection of patient reported outcome (PRO) data in clinical trials of antiepileptic drugs (AEDs), PRO results are not being routinely reported on European Medicines Agency (EMA) and Food and Drug Administration (FDA) product labels. This review aimed to evaluate epilepsy-specific PRO instruments against FDA regulatory standards for supporting label claims. Structured literature searches were conducted in Embase and Medline databases to identify epilepsy-specific PRO instruments. Only instruments that could potentially be impacted by pharmacological treatment, were completed by adults and had evidence of some validation work were selected for review. A total of 26 PROs were reviewed based on criteria developed from the FDA regulatory standards. The ability to meet these criteria was classified as either full, partial or no evidence, whereby partial reflected some evidence but not enough to comprehensively address the FDA regulatory standards. Most instruments provided partial evidence of content validity. Input from clinicians and literature was common although few involved patients in both item generation and cognitive debriefing. Construct validity was predominantly compromised by no evidence of a-priori hypotheses of expected relationships. Evidence for test-retest reliability and internal consistency was available for most PROs although few included complete results regarding all subscales and some failed to reach recommended thresholds. The ability to detect change and interpretation of change were not investigated in most instruments and no PROs had published evidence of a conceptual framework. The study concludes that none of the 26 have the full evidence required by the FDA to support a label claim, and all require further research to support their use as an endpoint. The Subjective Handicap of Epilepsy (SHE) and the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) have the fewest gaps that would need to be addressed through additional research prior to any FDA regulatory submission, although the NDDI-E was designed as a screening tool and is therefore unlikely to be suitable as an instrument for capturing change in a clinical trial and the SHE lacks the conceptual focus on signs and symptoms favoured by the FDA
Additional file 2: Figure S2. of Interpreting change from patient reported outcome (PRO) endpoints: patient global ratings of concept versus patient global ratings of change, a case study among osteoporosis patients
ROC curves identifying the best cut point (BCP, indicated by the arrow) of OPAQ-PF change scores for an improvement of 1 point on Mobility, Physical Positions, and Transfers ratings of change and ratings of concept at weeks 2 (no recent fracture patients) and 12 (recent fracture patients). (DOCX 188 kb
Lennox-Gastaut Syndrome (LGS): development of conceptual models of health-related quality of life (HRQL) for caregivers and children
LGS is a severe form of childhood epilepsy which is characterized by multiple seizures and cognitive
impairment. Semi-structured interviews were conducted with 40 parents of children with LGS in the US,
UK, and Italy. Parents were asked to report on their perceptions of the HRQL of their child and also to
describe the impact on their own HRQL. Thematic analysis was conducted to develop themes relating to
the impact on HRQL. The themes were organized into conceptual models of the impact of LGS on the
HRQL of the parent and the child. The models demonstrate the complex relationships between the
components of LGS and their impact on HRQL
Estimation of utilities in attention-deficit hyperactivity disorder for economic evaluations
Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial
The MM-015 trial assessed the effect of lenalidomide-based therapy on
health-related quality of life. Patients (n=459) with newly diagnosed
multiple myeloma aged 65 years or over were randomized 1:1:1 to nine
4-week cycles of lenalidomide, melphalan, and prednisone, followed by
lenalidomide maintenance; or lenalidomide, melphalan, and prednisone, or
melphalan and prednisone, with no maintenance therapy. Patients
completed health-related quality of life questionnaires at baseline,
after every third treatment cycle, and at treatment end. Health-related
quality of life improved in all treatment groups during induction
therapy. Patients receiving lenalidomide maintenance had the most
pronounced improvements, Global Health Status/Quality of Life (P<0.05),
Physical Functioning (P<0.01), and Side Effects of Treatment (P<0.05)
out of 6 pre-selected health-related quality of life domains. More
patients receiving lenalidomide maintenance achieved minimal important
differences (P<0.05 for Physical Functioning). Therefore, lenalidomide,
melphalan, and prednisone, followed by lenalidomide maintenance,
improves health-related quality of life in patients with newly diagnosed
multiple myeloma. (Clinicaltrials.gov identifier NCT00405756)